Royalty Term. (a) Royalties. Royalties under Section 4.3 will be payable on a country by country and Licensed Product-by-Licensed Product basis during the period commencing on the First Commercial Sale of such Licensed Product in the applicable Field in such country and ending upon the later of (i) the date of expiration, unenforceability or invalidation of the last Valid Claim of Penwest Patent Rights Covering such Licensed Product in such country of sale, and (ii) ten (10) years from the date of First Commercial Sale in such country (the “Royalty Term”).
Appears in 3 contracts
Samples: Exclusive License Agreement (Trevi Therapeutics, Inc.), Exclusive License Agreement (Trevi Therapeutics, Inc.), Exclusive License Agreement (Trevi Therapeutics, Inc.)
Royalty Term. (a) Royalties. Royalties The royalties due under Section 4.3 will 6.4(a) shall be payable on a country by country and Licensed Product-by-Licensed Product basis during the period commencing on Net Sales from the First Commercial Sale of such a particular Licensed Product in the applicable Field in such country and ending upon until the later of of, on a country-by-country basis, (i) the date of expiration, unenforceability or invalidation expiration of the last Valid Claim of Penwest Patent Rights Covering to expire patent in such country covering such Licensed Product or its use for which regulatory approval has been obtained in such country of salecountry, and or (ii) ten (10) years from the date of such First Commercial Sale in each such country. Such period during which royalties are payable with respect to a Licensed Product in a country (is referred to herein as the “Royalty Term”)” in such country with respect to such Licensed Product.
Appears in 2 contracts
Samples: License Agreement (Dov Pharmaceutical Inc), License Agreement (XTL Biopharmaceuticals LTD)
Royalty Term. (a) Royalties. Royalties under Section 4.3 will shall be payable paid on a country by country and Licensed Product-by-Licensed Product and country-by-country basis during in the period commencing on Licensee Territory from the First Commercial Sale of such Licensed Product in the applicable Field in such country and ending upon by or on behalf of Licensee, its Affiliates, or Sublicensees, until the later last to occur of (i) the date of expiration, unenforceability or invalidation expiration of the last last‑to‑expire Valid Claim of Penwest Patent Rights Covering the Ovid Patents (ii) the expiration of all Market Exclusivity covering such Licensed Product in such country of salecountry, and (iiiii) ten fifteen (1015) years from after the date of First Commercial Sale of such Product in such country (the “Royalty Term”).
Appears in 2 contracts
Samples: Collaboration and License Agreement (Ovid Therapeutics Inc.), Collaboration and License Agreement (Ovid Therapeutics Inc.)
Royalty Term. (a) Royalties. Royalties shall be paid under this Section 4.3 will be payable 6.5, on a country by country-by-country and Licensed Product-by-Licensed Product basis basis, on Net Sales during the period commencing of time beginning on the First Commercial Sale of such Licensed Product in the applicable Field in such country and ending upon continuing until the later of of: (i) the date of expiration, unenforceability expiration or invalidation abandonment of the last last-to-expire Valid Claim of Penwest Patent Rights in such country Covering such Licensed Product (a “Covering Claim” in such country of sale, for such Licensed Product); and (ii) ten (10) years from after the date of First Commercial Sale of such Licensed Product in such country (the “Royalty Term”).
Appears in 2 contracts
Samples: Development and License Agreement (Concert Pharmaceuticals, Inc.), Development and License Agreement (Concert Pharmaceuticals, Inc.)
Royalty Term. (a) Royalties. Royalties under Section 4.3 will shall be payable payable, on a country by country region-by-region and Licensed Product-by-Licensed Product basis during basis, from the period commencing beginning on the date of the First Commercial Sale of such Licensed Product in the applicable Field in such country and ending upon the later of (i) the date of expiration, unenforceability or invalidation of the last Valid Claim of Penwest Patent Rights Covering such Licensed Product in such country of sale, region in the Licensed Territory and (ii) ten (10) years from continuing unless the date of First Commercial Sale License is terminated earlier as provided in such country ARTICLE 9. (the “Royalty Term”)) For the avoidance of doubt, on a Product-by-Product and region-by-region basis, royalties shall not be payable on the Net Sales of the Products occurred after the Royalty Term.
Appears in 1 contract
Samples: Exclusive License Agreement (Gracell Biotechnologies Inc.)
Royalty Term. The royalties due under this Section 3.5 (aPayment of Royalties) Royalties. Royalties under Section 4.3 will shall be payable on Net Sales of a country by country and Licensed Product-by-Licensed particular Product basis during the period commencing on from the First Commercial Sale of such Licensed Product in the applicable Field in such country and ending upon until the later of of, on a country-by-country basis, (i) the date of expiration, unenforceability or invalidation expiration of the last Valid Claim of Penwest a Licensed Patent Rights Covering that Covers a Product in any such Licensed country, (ii) the expiration of any market exclusivity or data exclusivity granted by the applicable Regulatory Authority for such Product in such country of salecountry, and (iiiii) ten twelve (1012) years from after the date of First Commercial Sale of such Product in such country (the “Royalty Term”).
Appears in 1 contract
Royalty Term. (a) Royalties. Royalties under Section 4.3 will be payable paid under this Section 6.3, on a country by country-by-country and Licensed Product-by-Licensed Product basis during the period basis, commencing on First Commercial Sale of such Licensed Product in such country until the latest of: (i) the expiration of the last-to-expire Valid Claim of a Licensed Patent in such country that Covers such Licensed Product, (ii) [***] in such country covering such Licensed Product, and (iii) [***] of the First Commercial Sale of such Licensed Product in the applicable Field in such country and ending upon the later of (i) the date of expiration, unenforceability or invalidation of the last Valid Claim of Penwest Patent Rights Covering such Licensed Product in such country of sale, and (ii) ten (10) years from the date of First Commercial Sale in such country (the “Royalty Term”)..
Appears in 1 contract
Samples: License Agreement (Immunome Inc.)
Royalty Term. (a) Royalties. Royalties under Section 4.3 will 5.2 shall be payable on a country by country and Licensed Productcountry-by-Licensed Product country basis in the Territory during the period commencing on the First Commercial Sale of such a Licensed Product in any country in the applicable Field in such country Territory and ending upon the later to occur of (ia) the date of expiration, unenforceability or invalidation expiration of the last Valid Claim of Penwest an issued patent within Benuvia Patent Rights Covering such the respective Licensed Product in such the country of sale, and sale or country of manufacture; or (iib) ten fifteen (1015) years from the date of First Commercial Sale of the respective Licensed Product under this Agreement in such any country (the “Royalty Term”).
Appears in 1 contract
Samples: Development and License Agreement (Chromocell Therapeutics Corp)
Royalty Term. (a) Royalties. Royalties under Section 4.3 will 8.4(a) shall be payable payable, on a country by country and Licensed Product-by-Licensed Product basis and country-by-country basis, in the Licensed Territory, on the Net Sales of each Licensed Product during the period commencing on the of time beginning with First Commercial Sale of such a Licensed Product in the applicable Field in such country and ending upon on the later latest of (i) the date of expiration, unenforceability or invalidation of the last Valid Claim of Penwest Patent Rights Covering such Licensed Product in such country of sale, and (ii) ten (10) [***] years from the date of after First Commercial Sale in such country of such Licensed Product, (ii) the last to expire Valid Claim within the [***] that Covers the Licensed Product in such country, and (iii) [***] (“Royalty Term”).
Appears in 1 contract
Samples: Exclusive License Agreement (BridgeBio Pharma, Inc.)
Royalty Term. (a) Royalties. Royalties shall be paid under this Section 4.3 will be payable 4.5, on a country by country-by-country and Licensed Product-by-Licensed Product basis basis, during the period commencing on of time beginning from the First Commercial Sale of such Licensed Product in such country until the applicable Field expiration of the last-to-expire Valid Claim in any Licensor Patent in such country and ending upon that Covers the later composition of (i) matter of such Licensed Product, the date manufacture of expiration, unenforceability or invalidation of the last Valid Claim of Penwest Patent Rights Covering such Licensed Product in such country country, or a method of sale, and (ii) ten (10) years from the date use of First Commercial Sale such Licensed Product for an indication for which Regulatory Approval has been obtained in such country (the “Royalty Term”).
Appears in 1 contract
Samples: License Agreement (Corbus Pharmaceuticals Holdings, Inc.)